Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Amanda Feeney"'
Autor:
Sylvain Tshilombo, Romeo Bilugan, Amanda Feeney, Jonathan Im, Heather M. Kuntz, Kavita Gandhi, Besh Barcega, Jean Felix Babane, Vincent Ndebwanimana, Mindi Guptill
Publikováno v:
International Journal of Emergency Medicine, Vol 16, Iss 1, Pp 1-4 (2023)
Abstract Background Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease encountered in pediatrics with surgical repair being the definitive treatment. Long-term survival after surgical repair has improved; however, reported
Externí odkaz:
https://doaj.org/article/58035ebb4b9d4f639a25ec98f0f4ff51
Autor:
Rachel Campbell, Daniel S.J. Costa, Martin R. Stockler, Yeh Chen Lee, Jonathan A. Ledermann, Dominique Berton, Jalid Sehouli, Felicia T. Roncolato, Rachel O. Connell, Aikou Okamoto, Jane Bryce, Amit M. Oza, Elisabeth Avall-Lundqvist, Jonathan S. Berek, Anne Lanceley, Florence Joly, Felix Hilpert, Amanda Feeney, Marie C. Kaminsky, Katrina Diamante, Michael L. Friedlander, Madeleine T. King
Publikováno v:
Gynecologic Oncology. 166:254-262
The Measure of Ovarian Symptoms and Treatment (MOST) concerns is a validated patient-reported symptom assessment tool for assessing symptom benefit and adverse effects of palliative chemotherapy in women with recurrent ovarian cancer (ROC). We aimed
Autor:
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, Anne Lanceley, Florence Joly, Felix Hilpert, Alison Davis, Felicia T Roncolato, Aikou Okamoto, Jane Bryce, Paul Donnellan, Amit M Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Jonathan A Ledermann, Dominique Berton, Jalid Sehouli, Amanda Feeney, Marie-Christine Kaminsky, Katrina Diamante, Martin R Stockler, Michael L Friedlander
Publikováno v:
International Journal of Gynecologic Cancer. 32:761-768
Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurre
Autor:
Sylvain Tshilombo, Romeo Bilugan, Amanda Feeney, Jonathan Im, Heather M Kuntz, Kavita Gandhi, Besh Barcega, Jean Felix Babane, Vincent Ndebwanimana, Mindi Guptill
BackgroundTetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease encountered in pediatrics. Long-term survival after surgical repair has improved; however, reported mortality rates in unrepaired TOF are significant. Associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1244daca6fdcf960893873f6cd113e02
https://doi.org/10.21203/rs.3.rs-1778311/v1
https://doi.org/10.21203/rs.3.rs-1778311/v1
Autor:
Andrew R Clamp, R. Bowen, S. Nicum, Marcia Hall, Susana Banerjee, Rosemary Lord, G.J.S. Rustin, Jonathan A. Ledermann, R. Lilleywhite, Amanda Feeney, R.M. Glasspool, Agnieszka Michael, Allan Hackshaw, H.-M. Dehbi
Publikováno v:
Gynecologic Oncology. 159:692-698
We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer.Patients with relapsed ovarian, fallopian tube or primary perit
Autor:
Carien L. Creutzberg, Petronella B. Ottevanger, Annamaria Ferrero, Luis Souhami, Pearly Khaw, GH Westerveld, Diane Provencher, Gillian Thomas, Jan Pyman, V. Do, Annerie Slot, C Davidson, G. Wilson, Stephanie M. de Boer, Peter Hoskin, C M McLachlin, Michael A. Quinn, Deborah Gregory, Remi A. Nout, Hans W. Nijman, J.J. Jobsen, Tanja C. Stam, Vincent T.H.B.M. Smit, K Whitmarsh, Paul Bessette, Roy F.P.M. Kruitwagen, W Taylor, Dionyssios Katsaros, Chantal Hanzen, Henry C Kitchener, M McCormack, Prafull Ghatage, Dominique Berton-Rigaud, J.W.M. Mens, Melanie E Powell, Elisabeth Pras, Jonathan A. Ledermann, Karen W Verhoeven-Adema, Harmen Hollema, Andrea Lissoni, Linda Mileshkin, Anjana Anand, Amanda Feeney, Sergio Gribaudo, Marie-Helene Baron, R Allerton, Hein Putter, Colin D. Johnson, P. Symonds, Ina M. Jürgenliemk-Schulz, Romerai D'Amico, Ilka Kolodziej, M Adusumalli, Naveena Singh, G Artioli, An Snyers, R Wade, Christine Haie-Meder, Roldano Fossati, Nicole Tubiana-Mathieu, Anthony Fyles, Silvestro Carinelli, Anne Capp, Alexandra J. Stewart, Kaj De Winter, B. van Triest, L.C.H.W. Lutgens, Susan Brooks, E. Van der Steen-Banasik, Pierre Duvillard, Pvc Rittenberg, Alessandro Colombo
Publikováno v:
Lancet Oncology, 20, 1273-1285
Lancet oncology, 20(9), 1273-1285. Elsevier Science
The Lancet Oncology, 20(9), 1273-1285
PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X
The Lancet Oncology
Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC
Lancet Oncology, 20, 9, pp. 1273-1285
Lancet oncology, 20(9), 1273-1285. Elsevier Science
The Lancet Oncology, 20(9), 1273-1285
PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X
The Lancet Oncology
Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC
Lancet Oncology, 20, 9, pp. 1273-1285
BACKGROUND:The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and
Autor:
Ina M. Jürgenliemk-Schulz, Ludy C.H.W. Lutgens, Marie Helene Baron, V. Do, Karen W Verhoeven-Adema, C. Post, Nelleke Ottevanger, Carien L. Creutzberg, Christine Haie-Meder, Jonathan A. Ledermann, Susan Brooks, Geraldine Goss, Linda Mileshkin, Anthony Fyles, Paul Bessette, Melanie E Powell, Roldano Fossati, Mary McCormack, Stephanie M. de Boer, Henry C Kitchener, Andrea Lissoni, Alexandra Leary, Vincent T.H.B.M. Smit, Romerai D'Amico, Amanda Feeney, Dionyssios Katsaros, Remi A. Nout, Hans W. Nijman, Hein Putter, Prafull Ghatage, Pearly Khaw
Publikováno v:
International Journal of Radiation Oncology-Biology-Physics, 109(4), 975-986. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology, Biology, Physics, 109, 975-986
International Journal of Radiation Oncology Biology Physics, 109(4), 975-986. Elsevier Science
International Journal of Radiation Oncology, Biology, Physics, 109(4), 975-986. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology, Biology, Physics, 109, 4, pp. 975-986
International journal of radiation oncology, biology, physics, 109(4), 975-986. Elsevier
International Journal of Radiation Oncology, Biology, Physics, 109, 975-986
International Journal of Radiation Oncology Biology Physics, 109(4), 975-986. Elsevier Science
International Journal of Radiation Oncology, Biology, Physics, 109(4), 975-986. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology, Biology, Physics, 109, 4, pp. 975-986
International journal of radiation oncology, biology, physics, 109(4), 975-986. Elsevier
Contains fulltext : 232064.pdf (Publisher’s version ) (Open Access) PURPOSE: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiation therapy versus pelvic radiation t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2798f409593ab83be7f21b7d7f100a58
http://www.redjournal.org/article/S0360301620344473/pdf
http://www.redjournal.org/article/S0360301620344473/pdf
Autor:
Osnat Elyashiv, Gita Parmar, Gordon C Jayson, Shibani Nicum, Amanda Feeney, Fatima El-Khouly, Nicholas Counsell, Laura Farrelly, Linda Mileshkin, Eva Burnett, Ian Macdonald, Jonathan A. Ledermann, Andreia Neto, Esther Arthur-Darkwa, Charlie Gourley
Publikováno v:
Elyashiv, O, Ledermann, J, Parmar, G, Farrelly, L, Counsell, N, Feeney, A, El-khouly, F, Macdonald, I, Neto, A, Arthur-darkwa, E, Burnett, E, Jayson, G C, Mileshkin, L, Gourley, C & Nicum, S 2020, ' ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy ', International Journal of Gynecological Cancer, pp. ijgc-2020-002073 . https://doi.org/10.1136/ijgc-2020-002073
BackgroundTwo novel biological agents—cediranib targeting angiogenesis, and olaparib targeting DNA repair processes—have individually led to an improvement in ovarian cancer control. The aim of ICON9 is to investigate the combination of cediranib
Autor:
Remi A. Nout, Hans W. Nijman, Pearly Khaw, Paul Bessette, S. M. de Boer, Carien L. Creutzberg, Petronella B. Ottevanger, D. Katsaros, Christine Haie-Meder, Romerai D'Amico, Marie-Helene Baron, Vthbm Smit, Jonathan A. Ledermann, Amanda Feeney, Anthony Fyles, C. Post, M. E. Powell, L.C.H.W. Lutgens, Susan Brooks, Hein Putter, Karen W Verhoeven-Adema, I.M. Jürgenliemk-Schulz, Henry C Kitchener, Linda Mileshkin
Publikováno v:
Radiotherapy and Oncology. 152:S199-S200
Autor:
Emma Hudson, Amanda Feeney, Tim Mould, Naveena Singh, Abigail Sharp, Henry C Kitchener, Carien L. Creutzberg, Laura Hughes, Hans W. Nijman, Peey-Sei Kok, Raji Ganesan, Laura Farrelly, Allan Hackshaw, Jeremy Twigg, Alison Brand, Richard J. Edmondson, Jonathan A. Ledermann
Publikováno v:
Journal of Clinical Oncology. 36:TPS5615-TPS5615
TPS5615Background: The benefit of lymphadenectomy on survival in stage 1 endometrial cancer remains uncertain. STATEC is a surgical trial designed to evaluate the use of nodal status after lymph no...